Polynovo Ltd PNV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.90
- Day Range
- A$0.89–0.91
- 52-Week Range
- A$0.81–1.56
- Bid/Ask
- A$0.90 / A$0.91
- Shares Outstanding
- 690.84M
- Market Cap
- A$625.21M
- Volume/Avg
- 450,288 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 47.59
- Price/Sales
- 4.38
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Polynovo earns majority of its revenue from U.S sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 8
- Website
- https://www.polynovo.com
Valuation
|
Metric
|
PNV
|
|---|---|
Price/Earnings (Normalized) | 47.59 |
Price/Book Value | 6.86 |
Price/Sales | 4.38 |
Price/Cash Flow | 27.23 |
Price/Earnings
PNV
Financial Strength
|
Metric
|
PNV
|
|---|---|
Quick Ratio | 2.34 |
Current Ratio | 2.99 |
Interest Coverage | 9.34 |
Quick Ratio
PNV
Profitability
|
Metric
|
PNV
|
|---|---|
Return on Assets (Normalized) | 5.41% |
Return on Equity (Normalized) | 8.06% |
Return on Invested Capital (Normalized) | 7.40% |
Return on Assets
PNV
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|Hh%^LdV | LOCK|Pgprd | $167B | |||
| Medtronic PLC
MDT
| LOCK|D>!&#? | LOCK|t<$bT | $111B | |||
| Stryker Corp
SYK
| LOCK|d!$TpStb | LOCK|wY# | $105B | |||
| Boston Scientific Corp
BSX
| LOCK|>Xtc%!% | LOCK|V&!C | $63B | |||
| Edwards Lifesciences Corp
EW
| LOCK|^H^>&G<? | LOCK|S^fKW | $49B | |||
| DexCom Inc
DXCM
| LOCK|@SS?&%?< | LOCK|@^$n! | $33B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|l^^H@r | LOCK|Qd | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|>& | LOCK|!x< | $23B | |||
| Steris PLC
STE
| LOCK|TfN%tB | LOCK|CJWN | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|>Nc%>%n | LOCK|%!v | $17B |
United States